Alex

Alex is a writer and digital content enthusiast who enjoys covering technology, current trends, useful tips, and topics that matter to everyday readers. With a focus on clear, informative, and easy-to-understand content, Alex aims to provide readers with practical insights and interesting perspectives across a wide range of subjects.

Wire Stories

KDDI Uses Wind River Studio for Its Commercial Deployment of 5G Open vRAN Sites in Japan

Alex February 15, 2023

ALAMEDA, Calif.--(BUSINESS WIRE)--#5g--Wind River®, a global leader in delivering software for mission-critical intelligent systems, today announced that Wind River Studio...

SHMP_Logo_6-11-2021-2

NaturalShrimp Collaborates with Australian Companies in a Prawn Farm Wastewater Trial

Alex February 15, 2023

DALLAS--(BUSINESS WIRE)--NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS...

SHMP_Logo_6-11-2021-1

NaturalShrimp Collaborates with Australian Companies in a Prawn Farm Wastewater Trial

Alex February 15, 2023

DALLAS--(BUSINESS WIRE)--NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS...

SHMP_Logo_6-11-2021

NaturalShrimp Collaborates with Australian Companies in a Prawn Farm Wastewater Trial

Alex February 15, 2023

DALLAS--(BUSINESS WIRE)--NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS...

Wire Stories

TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)

Alex February 15, 2023

Patients underwent BNCT using TAE Life Sciences’ Neutron Beam System as part of Neuboron Medical Group’s NeuPex System at Xiamen...

Wire Stories

TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)

Alex February 15, 2023

Patients underwent BNCT using TAE Life Sciences’ Neutron Beam System as part of Neuboron Medical Group’s NeuPex System at Xiamen...

Wire Stories

TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)

Alex February 15, 2023

Patients underwent BNCT using TAE Life Sciences’ Neutron Beam System as part of Neuboron Medical Group’s NeuPex System at Xiamen...

Anteris_Logo-2

Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts

Alex February 15, 2023

Company Funded Through Results of U.S. Early Feasibility Study of DurAVR™ BRISBANE, Australia and EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Ltd (ASX:...

Anteris_Logo-1

Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts

Alex February 15, 2023

Company Funded Through Results of U.S. Early Feasibility Study of DurAVR™ BRISBANE, Australia and EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Ltd (ASX:...

Anteris_Logo

Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts

Alex February 15, 2023

Company Funded Through Results of U.S. Early Feasibility Study of DurAVR™ BRISBANE, Australia and EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Ltd (ASX:...

VBI_Vaccines_Logo_Horiz_RGB-2

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

Alex February 15, 2023

BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and...

VBI_Vaccines_Logo_Horiz_RGB-1

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

Alex February 15, 2023

BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and...

VBI_Vaccines_Logo_Horiz_RGB

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

Alex February 15, 2023

BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and...

2023-2

Asahi Kasei Completes Second Plant for Ceolus™ Microcrystalline Cellulose

Alex February 15, 2023

NEW YORK & DÜSSELDORF, Germany & TOKYO--(BUSINESS WIRE)--#asahikasei--Asahi Kasei, a diversified Japanese multinational company, has completed the construction of its...

2023

Asahi Kasei Completes Second Plant for Ceolus™ Microcrystalline Cellulose

Alex February 15, 2023

NEW YORK & DÜSSELDORF, Germany & TOKYO--(BUSINESS WIRE)--#asahikasei--Asahi Kasei, a diversified Japanese multinational company, has completed the construction of its...